Aptose Biosciences Inc. (LTI.F)
| Previous close | 1.1200 |
| Open | 1.0600 |
| Bid | 1.1400 x N/A |
| Ask | 1.1500 x N/A |
| Day's range | 1.0600 - 1.0600 |
| 52-week range | 1.0600 - 7.3800 |
| Volume | |
| Avg. volume | 51 |
| Market cap | 18.235M |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.0700 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWhat Makes Aptose Biosciences (APTO) a New Buy Stock
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Insider MonkeyAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript March 26, 2024 Aptose Biosciences Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name is Jonathan and I will be your conference operator today. I would like […]
GlobeNewswireAptose Reports Results for the Fourth Quarter and Full Year 2023
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired Levels and Positions for Future TrialsConference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated or
